FDA+ roundup: More than 2 years after a CRL, Lexicon is still battling the decision; UK pharma industry weighs direction of MHRA
Back in March 2019, the FDA made clear to Sanofi and its partner Lexicon Pharmaceuticals that it couldn’t approve the application for their diabetes drug …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
